JP2013529087A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013529087A5 JP2013529087A5 JP2013511358A JP2013511358A JP2013529087A5 JP 2013529087 A5 JP2013529087 A5 JP 2013529087A5 JP 2013511358 A JP2013511358 A JP 2013511358A JP 2013511358 A JP2013511358 A JP 2013511358A JP 2013529087 A5 JP2013529087 A5 JP 2013529087A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- bacterium
- subject
- streptococcus thermophilus
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000894006 Bacteria Species 0.000 claims description 89
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 79
- 238000000034 method Methods 0.000 claims description 62
- 241000194020 Streptococcus thermophilus Species 0.000 claims description 40
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 36
- 239000000203 mixture Substances 0.000 claims description 33
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 33
- 229920001184 polypeptide Polymers 0.000 claims description 28
- 210000000941 bile Anatomy 0.000 claims description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 21
- 208000035475 disorder Diseases 0.000 claims description 21
- 208000035143 Bacterial infection Diseases 0.000 claims description 18
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 18
- 239000002773 nucleotide Substances 0.000 claims description 16
- 125000003729 nucleotide group Chemical group 0.000 claims description 16
- 208000037384 Clostridium Infections Diseases 0.000 claims description 12
- 206010009657 Clostridium difficile colitis Diseases 0.000 claims description 12
- 206010054236 Clostridium difficile infection Diseases 0.000 claims description 12
- 239000002157 polynucleotide Substances 0.000 claims description 12
- 102000040430 polynucleotide Human genes 0.000 claims description 12
- 108091033319 polynucleotide Proteins 0.000 claims description 12
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 10
- 208000010643 digestive system disease Diseases 0.000 claims description 9
- 208000018685 gastrointestinal system disease Diseases 0.000 claims description 9
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 235000013305 food Nutrition 0.000 claims description 7
- 108090000695 Cytokines Proteins 0.000 claims description 6
- 102000004127 Cytokines Human genes 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 6
- 241001633172 Streptococcus thermophilus LMD-9 Species 0.000 claims description 6
- 230000002757 inflammatory effect Effects 0.000 claims description 6
- 239000006041 probiotic Substances 0.000 claims description 6
- 230000000529 probiotic effect Effects 0.000 claims description 6
- 235000018291 probiotics Nutrition 0.000 claims description 6
- 230000000770 proinflammatory effect Effects 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 230000035945 sensitivity Effects 0.000 claims description 4
- 102100023688 Eotaxin Human genes 0.000 claims description 3
- 101710139422 Eotaxin Proteins 0.000 claims description 3
- 206010061218 Inflammation Diseases 0.000 claims description 3
- 102000049772 Interleukin-16 Human genes 0.000 claims description 3
- 101800003050 Interleukin-16 Proteins 0.000 claims description 3
- 102100030703 Interleukin-22 Human genes 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 3
- 235000013365 dairy product Nutrition 0.000 claims description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 3
- 208000027866 inflammatory disease Diseases 0.000 claims description 3
- 230000004054 inflammatory process Effects 0.000 claims description 3
- 108010074109 interleukin-22 Proteins 0.000 claims description 3
- 244000144972 livestock Species 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims 3
- 230000001580 bacterial effect Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34610710P | 2010-05-19 | 2010-05-19 | |
| US61/346,107 | 2010-05-19 | ||
| US201161436452P | 2011-01-26 | 2011-01-26 | |
| US61/436,452 | 2011-01-26 | ||
| PCT/US2011/037149 WO2011146715A1 (en) | 2010-05-19 | 2011-05-19 | Compositions and methods for the delivery of therapeutic peptides |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013529087A JP2013529087A (ja) | 2013-07-18 |
| JP2013529087A5 true JP2013529087A5 (enExample) | 2014-07-03 |
| JP5871911B2 JP5871911B2 (ja) | 2016-03-01 |
Family
ID=44121330
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013511358A Expired - Fee Related JP5871911B2 (ja) | 2010-05-19 | 2011-05-19 | 治療用ペプチドの送達のための組成物および方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US9040302B2 (enExample) |
| EP (1) | EP2571894A1 (enExample) |
| JP (1) | JP5871911B2 (enExample) |
| CN (1) | CN103221420A (enExample) |
| WO (1) | WO2011146715A1 (enExample) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9585920B2 (en) | 2011-02-04 | 2017-03-07 | Katherine Rose Kovarik | Method and system for treating cancer cachexia |
| US9457077B2 (en) | 2009-11-18 | 2016-10-04 | Katherine Rose Kovarik | Method and system for targeting the microbiome to promote health and treat allergic and inflammatory diseases |
| US12279989B2 (en) | 2011-02-04 | 2025-04-22 | Seed Health, Inc. | Method and system for increasing beneficial bacteria and decreasing pathogenic bacteria in the oral cavity |
| US12257272B2 (en) | 2015-12-24 | 2025-03-25 | Seed Health, Inc. | Method and system for reducing the likelihood of developing depression in an individual |
| US11951139B2 (en) | 2015-11-30 | 2024-04-09 | Seed Health, Inc. | Method and system for reducing the likelihood of osteoporosis |
| US10835560B2 (en) | 2013-12-20 | 2020-11-17 | Joseph E. Kovarik | Reducing the likelihood of skin cancer in an individual human being |
| US11273187B2 (en) | 2015-11-30 | 2022-03-15 | Joseph E. Kovarik | Method and system for reducing the likelihood of developing depression in an individual |
| US10245288B2 (en) | 2011-02-04 | 2019-04-02 | Joseph E. Kovarik | Method and system for reducing the likelihood of developing NASH in an individual diagnosed with non-alcoholic fatty liver disease |
| US11419903B2 (en) | 2015-11-30 | 2022-08-23 | Seed Health, Inc. | Method and system for reducing the likelihood of osteoporosis |
| US11844720B2 (en) | 2011-02-04 | 2023-12-19 | Seed Health, Inc. | Method and system to reduce the likelihood of dental caries and halitosis |
| US11998479B2 (en) | 2011-02-04 | 2024-06-04 | Seed Health, Inc. | Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure |
| US10314865B2 (en) | 2011-02-04 | 2019-06-11 | Katherine Rose Kovarik | Method and system for treating cancer and other age-related diseases by extending the healthspan of a human |
| US10512661B2 (en) | 2011-02-04 | 2019-12-24 | Joseph E. Kovarik | Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease |
| US10583033B2 (en) | 2011-02-04 | 2020-03-10 | Katherine Rose Kovarik | Method and system for reducing the likelihood of a porphyromonas gingivalis infection in a human being |
| US11191665B2 (en) | 2011-02-04 | 2021-12-07 | Joseph E. Kovarik | Method and system for reducing the likelihood of a porphyromonas gingivalis infection in a human being |
| US10548761B2 (en) | 2011-02-04 | 2020-02-04 | Joseph E. Kovarik | Method and system for reducing the likelihood of colorectal cancer in a human being |
| US9987224B2 (en) | 2011-02-04 | 2018-06-05 | Joseph E. Kovarik | Method and system for preventing migraine headaches, cluster headaches and dizziness |
| US10086018B2 (en) | 2011-02-04 | 2018-10-02 | Joseph E. Kovarik | Method and system for reducing the likelihood of colorectal cancer in a human being |
| US11951140B2 (en) | 2011-02-04 | 2024-04-09 | Seed Health, Inc. | Modulation of an individual's gut microbiome to address osteoporosis and bone disease |
| US10111913B2 (en) | 2011-02-04 | 2018-10-30 | Joseph E. Kovarik | Method of reducing the likelihood of skin cancer in an individual human being |
| US10010568B2 (en) | 2011-02-04 | 2018-07-03 | Katherine Rose Kovarik | Method and system for reducing the likelihood of a spirochetes infection in a human being |
| US10687975B2 (en) | 2011-02-04 | 2020-06-23 | Joseph E. Kovarik | Method and system to facilitate the growth of desired bacteria in a human's mouth |
| US10842834B2 (en) | 2016-01-06 | 2020-11-24 | Joseph E. Kovarik | Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease |
| US10940169B2 (en) | 2015-11-30 | 2021-03-09 | Joseph E. Kovarik | Method for reducing the likelihood of developing cancer in an individual human being |
| US11357722B2 (en) | 2011-02-04 | 2022-06-14 | Seed Health, Inc. | Method and system for preventing sore throat in humans |
| US11523934B2 (en) | 2011-02-04 | 2022-12-13 | Seed Health, Inc. | Method and system to facilitate the growth of desired bacteria in a human's mouth |
| US9730967B2 (en) | 2011-02-04 | 2017-08-15 | Katherine Rose Kovarik | Method and system for treating cancer cachexia |
| US10085938B2 (en) | 2011-02-04 | 2018-10-02 | Joseph E. Kovarik | Method and system for preventing sore throat in humans |
| US12005085B2 (en) | 2013-12-20 | 2024-06-11 | Seed Health, Inc. | Probiotic method and composition for maintaining a healthy vaginal microbiome |
| US11969445B2 (en) | 2013-12-20 | 2024-04-30 | Seed Health, Inc. | Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH |
| US12246043B2 (en) | 2013-12-20 | 2025-03-11 | Seed Health, Inc. | Topical application to treat acne vulgaris |
| US11213552B2 (en) | 2015-11-30 | 2022-01-04 | Joseph E. Kovarik | Method for treating an individual suffering from a chronic infectious disease and cancer |
| US12329783B2 (en) | 2013-12-20 | 2025-06-17 | Seed Health, Inc. | Method and system to improve the health of a person's skin microbiome |
| US11839632B2 (en) | 2013-12-20 | 2023-12-12 | Seed Health, Inc. | Topical application of CRISPR-modified bacteria to treat acne vulgaris |
| US12318377B2 (en) | 2013-12-20 | 2025-06-03 | Seed Health, Inc. | Method and system for reducing the likelihood of a porphyromonas gingivalis infection in a human being |
| US11672835B2 (en) | 2013-12-20 | 2023-06-13 | Seed Health, Inc. | Method for treating individuals having cancer and who are receiving cancer immunotherapy |
| US11026982B2 (en) | 2015-11-30 | 2021-06-08 | Joseph E. Kovarik | Method for reducing the likelihood of developing bladder or colorectal cancer in an individual human being |
| US11998574B2 (en) | 2013-12-20 | 2024-06-04 | Seed Health, Inc. | Method and system for modulating an individual's skin microbiome |
| US11833177B2 (en) | 2013-12-20 | 2023-12-05 | Seed Health, Inc. | Probiotic to enhance an individual's skin microbiome |
| US11529379B2 (en) | 2013-12-20 | 2022-12-20 | Seed Health, Inc. | Method and system for reducing the likelihood of developing colorectal cancer in an individual human being |
| US11980643B2 (en) | 2013-12-20 | 2024-05-14 | Seed Health, Inc. | Method and system to modify an individual's gut-brain axis to provide neurocognitive protection |
| US11826388B2 (en) | 2013-12-20 | 2023-11-28 | Seed Health, Inc. | Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation |
| US11642382B2 (en) | 2013-12-20 | 2023-05-09 | Seed Health, Inc. | Method for treating an individual suffering from bladder cancer |
| CA2951739C (en) | 2014-07-01 | 2023-09-19 | Tntgamble, Inc. | Bi-layer dual release probiotic tablets |
| US12239706B2 (en) | 2015-11-30 | 2025-03-04 | Seed Health, Inc. | Method and system for protecting monarch butterflies from pesticides |
| US10086024B2 (en) | 2015-11-30 | 2018-10-02 | Joseph E. Kovarik | Method and system for protecting honey bees, bats and butterflies from neonicotinoid pesticides |
| US11529412B2 (en) | 2015-11-30 | 2022-12-20 | Seed Health, Inc. | Method and system for protecting honey bees from pesticides |
| US10933128B2 (en) | 2015-11-30 | 2021-03-02 | Joseph E. Kovarik | Method and system for protecting honey bees from pesticides |
| US10568916B2 (en) | 2015-11-30 | 2020-02-25 | Joseph E. Kovarik | Method and system for protecting honey bees, bats and butterflies from neonicotinoid pesticides |
| US10675347B2 (en) | 2015-11-30 | 2020-06-09 | Joseph E. Kovarik | Method and system for protecting honey bees from fipronil pesticides |
| WO2020055547A2 (en) | 2018-08-18 | 2020-03-19 | Seed Health, Inc. | Methods and compositions for honey bee health |
| US12161749B2 (en) * | 2018-08-24 | 2024-12-10 | North Carolina State University | Microneedle-array patches with glucose-responsive matrix for closed-loop insulin delivery |
| EP3930735A1 (en) | 2019-02-26 | 2022-01-05 | The Regents of the University of Colorado, a body corporate | Method and composition for treating gastrointestinal inflammatory disorders |
| CN114096658B (zh) * | 2019-06-24 | 2025-07-29 | Eos2021公司 | 包含益生菌的具有抗细菌和再上皮化作用的组合物 |
| CA3145919A1 (en) | 2019-08-19 | 2021-02-25 | Christopher Michel Kearney | Probiotic delivery of guided antimicrobial peptides |
| CN115869384B (zh) * | 2023-01-06 | 2023-05-23 | 北京朕荣国际生物科技有限公司 | 一种促进骨质更替改善的含肽药物组合物 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4336336A (en) | 1979-01-12 | 1982-06-22 | President And Fellows Of Harvard College | Fused gene and method of making and using same |
| ZA811368B (en) | 1980-03-24 | 1982-04-28 | Genentech Inc | Bacterial polypedtide expression employing tryptophan promoter-operator |
| US4551433A (en) | 1981-05-18 | 1985-11-05 | Genentech, Inc. | Microbial hybrid promoters |
| JPS59166086A (ja) | 1983-03-09 | 1984-09-19 | Teruhiko Beppu | 新規な発現型プラスミドとそれらを用いて仔牛プロキモシン遺伝子を大腸菌内で発現させる方法 |
| US4689406A (en) | 1983-08-10 | 1987-08-25 | Amgen | Enhancement of microbial expression of polypeptides |
| US4738921A (en) | 1984-09-27 | 1988-04-19 | Eli Lilly And Company | Derivative of the tryptophan operon for expression of fused gene products |
| US5028530A (en) | 1985-01-28 | 1991-07-02 | Xoma Corporation | AraB promoters and method of producing polypeptides, including cecropins, by microbiological techniques |
| JPS63123383A (ja) | 1986-11-11 | 1988-05-27 | Mitsubishi Kasei Corp | ハイブリツドプロモ−タ−、発現調節ｄｎａ配列および発現ベクタ− |
| US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
| US5561111A (en) | 1994-12-23 | 1996-10-01 | The University Of Virginia Patent Foundation | Stable glutamine derivatives for oral and intravenous rehydration and nutrition therapy |
| AU4251300A (en) * | 1999-05-07 | 2000-11-21 | University Of Virginia Patent Foundation | Biological production of stable glutamine, poly-glutamine derivatives in transgenic organisms and their use for therapeutic purposes |
| AU7131600A (en) | 1999-06-21 | 2001-01-09 | North Carolina State University | Acid-inducible promoters for gene expression |
| US6641808B1 (en) * | 1999-09-22 | 2003-11-04 | Lacpro Industries, Llc | Composition for treatment of obesity |
| JP2007531508A (ja) * | 2003-10-24 | 2007-11-08 | クイーンズランド ユニバーシティ オブ テクノロジー | タンパク質発現 |
| EP2248823A1 (en) * | 2009-04-28 | 2010-11-10 | Institut National de la Recherche Agronomique | New competence stimulating peptide |
-
2011
- 2011-05-19 EP EP11722973A patent/EP2571894A1/en not_active Withdrawn
- 2011-05-19 US US13/697,860 patent/US9040302B2/en not_active Expired - Fee Related
- 2011-05-19 WO PCT/US2011/037149 patent/WO2011146715A1/en not_active Ceased
- 2011-05-19 CN CN2011800356862A patent/CN103221420A/zh active Pending
- 2011-05-19 JP JP2013511358A patent/JP5871911B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013529087A5 (enExample) | ||
| KR101914248B1 (ko) | 박테리아 균주를 함유한 조성물 | |
| ES2787523T3 (es) | Composiciones que comprenden cepas bacterianas | |
| EP3209381B1 (en) | Compositions comprising bacterial strains | |
| CN108513544B (zh) | 包含细菌菌株的组合物 | |
| CN108271355B (zh) | 包含细菌菌株的组合物 | |
| ES2662617T3 (es) | Composiciones que comprenden cepas bacterianas | |
| CN113906129A (zh) | 嗜黏蛋白阿克曼菌eb-amdk19菌株及其用途 | |
| CN112933115B (zh) | Akkermansia muciniphila在治疗慢性胰腺炎方面的应用 | |
| CN115364122A (zh) | 包含细菌菌株的组合物 | |
| RU2019130941A (ru) | РЕКОМБИНАНТНАЯ BCG, СВЕРХЭКСПРЕССИРУЮЩАЯ PhoP-PhoR | |
| CN111629739A (zh) | 用于治疗或预防癌症的组合疗法 | |
| JPWO2020037271A5 (enExample) | ||
| KR20190070629A (ko) | HBD2(human beta-defensin 2) 또는 상기 유전자와 융합된 메르스 코르나 바이러스의 에피토프 단백질을 포함하는 메르스 코로나바이러스의 예방 또는 치료용 조성물 | |
| JP2021502391A5 (enExample) | ||
| Sleator et al. | Improving probiotic function using a pathobiotechnology approach | |
| Matsueda et al. | Efficacy and safety of acotiamide (Z-338) administered orally for 4-weeks in patients with functional dyspepsia: results from a randomized, double-blind, placebo-controlled phase III trial in Japan | |
| JP2022105169A (ja) | 細菌株を含む組成物 | |
| OA18795A (en) | Compositions comprising bacterial strains. | |
| HK40004476A (en) | Compositions comprising bacterial strains | |
| HK1253042B (zh) | 包含细菌菌株的组合物 | |
| HK1254166B (zh) | 包含细菌菌株的组合物 | |
| KR20170011221A (ko) | 클렙시엘라균 감염질환의 예방용 백신 |